Introduction

Regulation of eukaryotic gene expression implies mechanisms that permit transcription factors to gain access to chromatin packaged DNA sequences. The basic unit of chromatin, the nucleosome, consists of an octamer formed of two copies of each of the four core histones (H2A, H2B, H3, and H4) around which 147 bp DNA is wrapped in 1.65 left-handed superhelical turns [1]. Modulation of the structure and dynamics of nucleosomes is an important regulatory mechanism in all DNA-based processes and is catalyzed by chromatin remodeling complexes. Such complexes can either modify histone residues or use the energy of ATP hydrolysis to alter the relationship between histones and DNA [2,3].

The yeast SWI/SNF complex, the first ATP-dependent chromatin remodeling complex to be identified, is a 2-MDa complex of 11 subunits that regulates gene expression by catalyzing octamer transfer, nucleosome sliding, dinucleosome formation, and H2A/H2B displacement [4–6]. RSC, (Remodel the Structure of Chromatin) [7], is a closely related yeast SWI/SNF complex of 11 subunits that regulates gene expression by interaction of their receptors with hormone responsive elements (HREs) and recruitment of kinases, chromatin remodeling complexes, and coregulators to their target promoters. Here we show that in breast cancer cells the BAF, but not the closely related PBAF complex, is required for progesterone induction of several target genes including MMTV, where it catalyzes localized displacement of histones H2A and H2B and subsequent NF1 binding. PCAF is also needed for induction of progesterone target genes and acetylates histone H3 at K14, an epigenetic marker that interacts with the BAF subunits by anchoring the complex to chromatin. In the absence of PCAF, full loading of target promoters with hormone receptors and BAF is precluded, and induction is compromised. Thus, activation of hormone-responsive promoters requires cooperation of at least two chromatin remodeling activities, BAF and PCAF.

Two Chromatin Remodeling Activities Cooperate during Activation of Hormone Responsive Promoters

Guillermo Pablo Vicent1*, Roser Zaurin1*, A. Silvina Nacht1, Ang Li1, Jofre Font-Mateu1, Francois Le Dily1, Michiel Vermeulen2,3, Matthias Mann2, Miguel Beato1*

1 Centre de Regulacio´ Genomica (CRG), Universitat Pompeu Fabra, Parc de Recerca Biome`dica (PRBB), Barcelona, Spain, 2 Department of Proteomics and Signal Transduction, Max Planck Institute for Biochemistry, Martinsried, Germany, 3 Department of Physiological Chemistry and Cancer Genomics Centre, University Medical Center Utrecht, Utrecht, The Netherlands

Abstract

Steroid hormones regulate gene expression by interaction of their receptors with hormone responsive elements (HREs) and recruitment of kinases, chromatin remodeling complexes, and coregulators to their target promoters. Here we show that in breast cancer cells the BAF, but not the closely related PBAF complex, is required for progesterone induction of several target genes including MMTV, where it catalyzes localized displacement of histones H2A and H2B and subsequent NF1 binding. PCAF is also needed for induction of progesterone target genes and acetylates histone H3 at K14, an epigenetic marker that interacts with the BAF subunits by anchoring the complex to chromatin. In the absence of PCAF, full loading of target promoters with hormone receptors and BAF is precluded, and induction is compromised. Thus, activation of hormone-responsive promoters requires cooperation of at least two chromatin remodeling activities, BAF and PCAF.

Citation: Vicent GP, Zaurin R, Nacht AS, Li A, Font-Mateu J, et al. (2009) Two Chromatin Remodeling Activities Cooperate during Activation of Hormone Responsive Promoters. PLoS Genet 5(7): e1000567. doi:10.1371/journal.pgen.1000567

Editor: Yoshihide Hayashizaki, RIKEN Genomic Sciences Center, Japan

Received December 11, 2008; Accepted June 18, 2009; Published July 17, 2009

Copyright: © 2009 Vicent et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The experimental work was supported by grants from the Departament d’Innovació Universitat i Empresa (DIUIE), Ministerio de Educacio´ n y Ciencia (MEC) BMC 2003-02902, Consolider (CSD2006-00049) and Fondo de Investigación Sanitaria (FIS) PI0411605 and CP04/00087, and EU IP HERCII. GPV was a recipient of a fellowship of the Ramón y Cajal Programme. MV was supported by the Dutch Cancer Society (KWF/NKB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: miguel.beato@crg.es

† These authors contributed equally to this work.
Author Summary

In order to adapt its gene expression program to the needs of the environment, the cell must access the information stored in the DNA sequence that is tightly packaged into chromatin in the cell nucleus. How the cell manages to do it in a selective manner is still unclear. Here we show that, in breast cancer cells treated with the ovarian hormone progesterone, the hormone receptor recruits to the regulated genes two chromatin remodeling complexes that cooperate in opening the chromatin structure. One of the complexes puts a mark in a chromatin protein that anchors the other complex, enabling full gene activation. The present discovery highlights the importance of the concerted order of events for access to genomic information during activation of gene expression and reveals the intricacies of hormonal gene regulation.

mediated events [17,18], but the precise mechanism of action has not yet been elucidated.

The functional relationship between different chromatin remodeling enzymatic activities is of great interest. A remarkable interdependence has been described during transcriptional activation in S. cerevisiae between the SWI/SNF complex and the histone acetylation complex SAGA [19]. Bromodomains of the RSC complex have been shown to recognize acetylated H3K14 [20]. HAT activity stabilizes SWI/SNF binding to promoter nucleosomes providing a mechanistic basis for the ordered recruitment of these complexes [21]. In mammalian cells, transcriptional activation by nuclear receptors requires multiple cofactors including CBP/p300, SWI/SNF and Mediator. The ordered recruitment of these cofactors to the promoters depends not only on the direct interactions between nuclear receptors and cofactors but also on cofactor-cofactor interaction and on histone modifications [22].

Gene regulation by steroid hormones is mediated by intracellular receptors, which upon hormone binding can activate signal transduction cascades and interact in the nucleus with other transcription factors and/or with dedicated DNA sequences, called hormone responsive elements (HREs) [23]. When ligand-receptor complexes interact with HREs they alter the transcriptional state of the associated genes via the recruitment of chromatin remodeling complexes and other coregulators to the target promoters [24,25]. The mouse mammary tumor virus (MMTV) long terminal-repeat sequence encompasses a promoter including within 140 bp five degenerated hormone responsive elements (HREs) and a binding site for nuclear factor 1 (NF1). In chromatin the MMTV promoter is organized into positioned nucleosomes [26], with a nucleosome located over the five HREs and the NF1 binding site [27]. On this promoter nucleosome, the binding site for NF1 is not accessible and only two of the five HREs, the strong palindromic HRE1 and the weak half palindrome HRE4, can be bound by hormone receptors, while the central HREs, in particular the palindromic HRE2 and the half palindrome HRE3, are not accessible for receptor binding [28]. Following hormone induction in vivo all HREs and the binding site for NF1 are occupied simultaneously on the surface of a nucleosome-like structure and a functional synergism is observed between progesterone receptor (PR) and NF1 [27].

Already 5 minutes after addition of hormone to breast cancer cells with an integrated copy of an MMTV-luc reporter, the cytoplasmic signaling cascade Src/Ras/Erk is activated via an interaction of PR with the estrogen receptor, which activates Src [29]. As a consequence of Erk activation, PR is phosphorylated, Msk1 is activated, and a ternary complex PR-Erk-Msk1 is recruited to nucleosome B [30]. Msk1 phosphorylates H3 at serine 10, a modification which is accompanied by acetylation at H3 lysine 14, displacement of HP1γ, and recruitment of RNA polymerase II [30]. Inhibition of Erk or Msk activation blocks H3K14 phosphorylation, H3K14 acetylation, and hormonal induction of MMTV and other progesterone target genes [30].

There have been several reports indicating a role for SWI/SNF, Brg1 and Brm in glucocorticoid regulation of MMTV transcription [31–33], but the situation with progesterone is less clear. The MMTV promoter assembled in minichromosomes with positioned nucleosomes [34] is activated by PR in a process involving a NURF-dependent mutual synergism between PR and NF1 [35]. Progestrone treatment of a breast cancer cell line carrying a single integrated copy of a MMTV transgene leads to recruitment of PR, SWI/SNF, and SNF2h-related complexes to the MMTV promoter, accompanied by selective displacement of histones H2A and H2B from nucleosome B [6,25]. Recently, the acidic N terminus of the Swi3p subunit of yeast SWI/SNF was identified as a novel H2A-H2B-binding domain required for ATP-dependent H2A/H2B dimer displacement [36]. Moreover, a characteristic and sharp DNase I hypersensitive site appears near the symmetry axis of the nucleosome encompassing the HREs [27]. The same hypersensitive site can be induced in the absence of hormone by treatment with low concentrations of histone deacetylases inhibitors, such as sodium butyrate or trichostatin A [37], suggesting that it can be initiated by a moderate increased in histone acetylation. However, the relationship between histone acetylation and ATP-dependent nucleosome remodeling following hormone treatment is not clear. To approach this question we have performed knockdown and ChIP experiments targeting human SWI/SNF complexes and histone acetyl transferases (HATs) in breast cancer cells.

Results

BAF is required for progesterone gene activation in T47D-MTVL cells and is recruited to the MMTV promoter upon induction

The requirement of Brm and Brg1 for MMTV promoter activation was assessed in T47D-MTVL cells transfected with specific siRNAs. When siRNA against Brg1 was used, the levels of Brm protein increased (Figure 1A, left panels) and viceversa (Figure 1A, middle panels). A significant reduction (80% and 55% for Brm and Brg1, respectively) of both ATPases was only observed when the two siRNAs were combined (Figure 1A, right panels). The levels of the two PR isoforms, PRB and PRA, were unaffected by Brg1 or Brm siRNAs (Figure 1A, third row). In cells transfected with control siRNA an eight-fold increase in MMTV-luc transcription was observed 8 hours after hormone treatment (Figure 1B). In cells transfected with siRNAs against either Brg1 or Brm, the induction was reduced by 30% and 20% respectively, whereas transfection of both siRNA simultaneously reduced the induction of the MMTV promoter by 60%, confirming the essential role of hSWI/SNF on MMTV promoter activation (Figure 1B). Progesterin induction of MYC and FOS, two other progesterone target genes, was also impaired by the combined siRNAs to a level similar to that observed with MMTV-luc (Figure 1C). However, not all hormone-dependent genes required SWI/SNF, as the combined siRNAs did not inhibit the progesterin induction of the cyclin D1 gene (Figure 1C).

To identify the nature of the Brm/Brg1-containing complex in T47D-MTVL cells, we performed western blotting against subunits of BAF and PBAF, the two distinctive hSWI/SNF complexes. Subunits of both complexes exist in T47D-MTVL cells but...
Figure 1. BAF is essential for MMTV promoter activity in T47D-MTVL cells. (A) Cells were transfected either with siRNA against Brg1, Brm, or both siRNAs combined as indicated. After 48 h the medium was replaced by fresh medium without serum. After one day in serum-free conditions, cells were lysed and the levels of Brm, Brg1, PR and tubulin were determined by Western blotting. C, control siRNA. (B) Cells were transfected with Control, Brg1 and Brm siRNAs as described in (A). After one day in serum-free conditions, cells were incubated with 10 nM R5020 for 8 hs and total RNA was prepared, cDNA was generated and used as template for real time PCR with luciferase oligonucleotides. The values represent the mean and standard deviation from 3 experiments performed in duplicate. (C) Cells were transfected with Control, Brg1 and Brm siRNAs as described in (A) and treated with 10 nM R5020. CDNA was generated and used as template for real-time PCR using specific c-Fos, c-Myc, Cyclin D1 and GAPDH primers. The values represent the mean±SD of 3 experiments performed in duplicate. (D) Cells were transfected with Control and BAF57 siRNAs as described in (A) and treated with 10 nM R5020. Left: BAF57 levels were analyzed by Western blotting. Right: RNA was extracted, cDNA was generated and used as template for real-time PCR with luciferase oligonucleotides. The values represent the mean±SD of 2 experiments performed in duplicate. (E) Cells were transfected with Control and BAF250 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (F) Cells were transfected with Control and BAF180 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (G) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (H) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (I) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (J) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (K) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (L) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (M) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (N) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (O) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (P) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (Q) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (R) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (S) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (T) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (U) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (V) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (W) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (X) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (Y) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. (Z) Cells were transfected with Control and BAF200 siRNAs as described in (A) and (D). The values represent the mean±SD of 2 experiments performed in duplicate. doi:10.1371/journal.pgen.1000567.g001
hormonal induction in T47D-MTVL cells

BAF57 and BAF250 interact with progesterone receptor

These studies contain BAF57. BAF and PBAF complexes in the breast cancer cell lines used for Brm (Figure 1F, lane 2 and data not shown). We conclude that BAF and PBAF complexes in the breast cancer cell lines used for these studies contain BAF57.

To further identify the specific complex recruited to the MMTV promoter, we performed ChIP experiments using antibodies recognizing specific components of the BAF and PBAF complexes. Simultaneously with the recruitment of PR to the MMTV promoter after hormone treatment, we observed recruitment of Brml, Brgm, BAF250 and BAF57 (Figure 1G). In contrast, BAF150 and BAF200, two of the specific subunits of PBAF, were not recruited to the MMTV promoter after hormone treatment (Figure 1G, third and fourth rows from the bottom). While they were recruited to the RAR/R2 promoter after retinoic acid treatment in U937 cells (Figure S2A). Moreover, siRNA mediated downregulation of BAF180 in T47D-MTVL cells did not influence hormonal induction of the MMTV promoter (Figure S2B). Thus, BAF complexes containing either one of the two related ATPases together with BAF250 and BAF57 are recruited to the MMTV promoter along with PR and likely mediate promoter transactivation.

BAF57 and BAF250 interact with progesterone receptor in T47D-MTVL cells

BAF57 has been shown to directly interact with the androgen and estrogen receptors [38,39]. We used co-immunoprecipitation experiments to test whether BAF57 forms a complex with PR in cultured cells. In the absence of hormone, a certain proportion of BAF57 already coprecipitated with PR probably due to the large proportion of PR molecules already present in the nucleus in the uninduced state; however 30 minutes after hormone addition the extent of coprecipitation was increased (Figure 2A, lanes 4 and 5). In contrast, no complex of PR with the PBAF specific subunit, BAF180 was observed independently of the addition of the hormone (Figure 2B). As a positive control for this experiment we used BAF250, a known BAF specific subunit [40]. BAF250 as BAF57 also showed a hormone-dependent interaction with PR (Figure 2B, lanes 2 and 3).

The PR-BAF57 interaction is likely direct, as activated ligand-bound PR interacts with GST-BAF57 in pulldown studies (Figure 2D, lane 2). Deletion mutants lacking either the C-terminal domain or the N-terminal domain, or containing only the central NHR1 domain (Figure 2C, left panel), could not form a complex with PR in GST-pulldown experiments (Figure 2D top row, lanes 3–5).

The fact that BAF57 is present in both BAF and PBAF complexes but only BAF is recruited to the target promoters indicate that either the PR-BAF57 interaction is not sufficient for recruitment of the complex or BAF57 can only interact with PR in the context of the BAF complex but not when integrated in the PBAF complex.

Acetylation on histone H3K14 by PCAF is required for hormonal induction

As the central ATPases of the BAF complex, Brml and Brm, both contain bromodomains that recognize acetylated lysines [41,42] and have been shown to bind acetylated histone H3 and H4 tails [43,44], we wondered about possible roles of histone acetyltransferases (HATs) in hormone induction. Using siRNAs we knocked down PCAF and/or SRC1, which are known to be recruited to the MMTV promoter upon induction [6,30] (Figure 3A). We do not have an explanation for the enhancement of the unspecific band (marked with an asterisk in Figure 3A, first row, lanes 2 and 4). When siPCAF was used, there was a 50% reduction of the MMTV induction (Figure 3A, right panel) paralleling the decrease in PCAF protein (Figure 3A, left panel); whereas siSRC1 caused only a 15% decrease (Figure 3A, right panel). The combination of the two siRNAs decreased induction by 62% (Figure 3A, right panel), indicating that PCAF is the more relevant HAT in hormonal activation of MMTV. PCAF depletion also decreased induction of other progesterone target genes such as MYC and FOS (Figure 3B), which were shown to depend on BAF.

The need for the catalytic activity of PCAF in regulating MMTV promoter was studied in T47D-MTVL cells transfected with wild type PCAF or an enzymatic deficient mutant (PCAFAHAT). While transfection of wild type PCAF further increased the level of activity obtained after hormone addition, transfection of PCAFAHAT did not further stimulate the MMTV promoter (Figure 3C). Although PCAF and PCAFAHAT are expressed at similar levels (data not shown), PCAFAHAT does not act as a dominant negative mutant possibly because its levels are not sufficient to compete with endogenous PCAF in transient transfection. Similar results were obtained when MYC and FOS genes were analysed (data not shown). Thus, the catalytic activity of PCAF is required for transcriptional activation of those progesterin target genes, which induction depends on BAF.

Regarding other acetyl transferases, no decrease in hormone-dependent activation of the MMTV was observed after transfection with specific siRNAs against GCN5 (data not shown).

Acetylated H3 lysine 14 anchors the BAF complex on the promoter

We next tested the influence of histone acetylation on BAF recruitment to the MMTV promoter. In control cells hormone treatment induced increased acetylation of H3K14 accompanied by recruitment of BAF57 and BAF250, whereas knockdown of PCAF and SRC1 abrogated K14 acetylation and markedly reduced BAF57 and BAF250 loading on the promoter (Figure 3D, compare lanes 1–2 vs 3–4; quantification by real time PCR is shown in the right panel). To test whether H3K14 acetylation and BAF binding take place on the same promoter, we performed sequential ChIP (re-ChIP) experiments in the MMTV, FOS and the MYC promoters. Hormone treatment induced increased acetylation of H3K14 accompanied by recruitment of BAF250 to the corresponding promoters (Figure 3E, lanes 5 and 6), indicating that the H3K14 acetylation and BAF recruitment occur in the same genomic region. In contrast, control re-ChIPs performed with irrelevant IgG as first antibody showed no amplification product (Figure 3E, lanes 3 and 4).

To test whether the association of H3K14 acetylation and BAF is a general phenomenon, we performed co-immunoprecipitation of total hormone-treated chromatin followed by western blot. This seems to be the case, as immunoprecipitation with antibody against acetylated H3K14 co-precipitated BAF155 (Figure 3F) and Brml (data not shown).

We next used pull-down experiments with T47D-MTVL nuclear extracts and biotinylated peptides of H3 and H4 tails containing various modifications to test whether H3K14 acetylation influences the binding affinity of the BAF complex for histone tails. Histone H1 was used as loading control (Figure 4A, lower
We detected binding to histone tails containing H3K14ac of nearly all subunits of the BAF and PBAF complexes, namely Brg1, Brm, BAF170, BAF155, BAF57, BAF180 and SNF5 (Figure 4A, lanes 4, 5, 7, and 8). Similar results were also obtained using HeLa nuclear extracts (data not shown). Moreover, binding of BAF and PBAF complexes to H3 peptides depends solely on H3K14ac and it is not affected by acetylation, phosphorylation or methylation of adjacent residues. Peptides carrying additional modifications, such as K4me3, K9ac, K9me3, or S10p, exhibited similar affinity for BAF subunits as those carrying only K14ac (Figure 4A lanes 5, 7, 8 and data not shown). H3 peptides acetylated at K9 and pan-acetylated (K5, 8, 12, 16) H4 peptides did not exhibit preferential BAF affinity (Figure 4A lanes 3, 10 and 11). Although H4K8 acetylation takes place very early after progesterone addition to T47D-MTVL cells (Figure 4B, upper panel), we found here no binding of the BAF complex to acetylated H4 peptides. The PBAF specific subunit, BAF180 showed the same behaviour as the BAF subunits when incubated with the modified peptides (Figure 4A, third row from the top). It is important to note, that we detected a faint and consistent binding of PR to all tested H3 and H4 peptides without any preference for particular epigenetic modification, indicating that PR is not acting as a bridging factor for the binding of BAF complex to the K14 acetylated peptides (Figure 4A, second row from the bottom). A similar behaviour was observed.
Figure 3. Acetylation on histone H3K14 by PCAF is essential for hormonal transactivation in T47D-MTVL cells. (A) Left: Cells were transfected with the indicated siRNAs and the levels of PCAF, SRC1, and tubulin were determined by Western blotting. The asterisks indicate inespecific bands. Right: Cells were transfected with the indicated siRNAs and treated with 10 nM R5020 for 6 h. RNA was extracted, cDNA was generated and used as template for real time PCR with luciferase oligonucleotides. The values represent the mean and standard deviation from 3 experiments performed in duplicate. (B) Cells were transfected with siRNAs, treated with 10 nM R5020 as indicated and the levels of c-Fos and c-Myc mRNAs were analyzed by RT–PCR. The values represent the mean and standard deviation from 2 experiments performed in duplicate. (C) Cells were transfected with PCAF or PCAF HAT mutant (PCAF ΔHAT), treated with hormone as indicated and transcription from the MMTV promoter was determined as in (B). An empty vector was used as control. The values represent the mean and standard deviation from 2 experiments performed in duplicate. (D) Left: Cells transfected with the siRNAs and treated with hormone as indicated were subjected to ChIP assays with α-BAF57, α-BAF250 and α-K14acH3. The precipitated DNA fragments were subjected to PCR analysis to test for the presence of sequences corresponding to the MMTV nucleosome B. A representative of three independent experiments is shown. Right: quantification of the results by real time PCR from two experiments performed in duplicate. (E) Cells were treated with R5020 as indicated and subjected to re-ChIP assays with α-H3K14ac and IgG (first IP) followed by α-BAF250 for the second IP. Precipitated DNA was analysed by PCR for the presence of sequences corresponding to the MMTV, c-Fos and c-Myc PR binding regions. (F) Cells were treated for 30 min with R5020, lysed and chromatin was immunoprecipitated either with α-H3K14ac or with normal rabbit IgG as a negative control (IgG). IPs were analyzed by western blot using α-BAF155 and α-H3K14ac.

doi:10.1371/journal.pgen.1000567.g003
Figure 4. The BAF complex binds preferentially to histone H3K14ac and promotes H2A displacement. (A) Nuclear extracts derived from T47D-MTVL cells were used for pulldown experiments with the indicated H3 and H4 tail peptides coupled to beads. Immunoblotting was performed for the presence of components of the BAF and PBAF complex, histone H1 and PR. (B) Cells were untreated (0) or treated for 5 and 30 min with 10 nM R-5020 and subjected to ChIP assays with α-H4K8ac and α-H3K9ac specific antibodies. The precipitated DNA fragments were subjected to PCR analysis to test for the presence of sequences corresponding to the MMTV nucleosome B. Input material (1%) is shown for comparison. A representative of three independent experiments is shown. (C) Quantification of the interaction of selected human SWI/SNF subunits with the indicated H3 tail acetylated peptides. SILAC ratios represent the relative abundance of the 'heavy' (modified) to the 'light' (unmodified) peptide. The variation (in %) and the number of quantified peptides are indicated. (D) Left: T47D-MTVL cells were transfected with siRNAs and treated with hormone as indicated, subjected to ChIP assays using α-NF1, α-PR and α-H2A and primers for MMTV nucleosome B. Right: quantification of the results by real time PCR. A representative of three independent experiments is shown.

doi:10.1371/journal.pgen.1000567.g004
BAF and PCAF Cooperate in MMTV Induction

Discussion

The results of this study contribute to a better understanding of the molecular mechanisms of promoter activation by progesterone. We have shown previously that PR interacts with an exposed HRE on the surface of a nucleosome on the MMTV promoter [27] and recruits Brg1/Brm-containing complexes [6]. Here, we demonstrate the need of the hSWI/SNF complex, known as BAF, for activation of MMTV and other progesterone target genes. We show that BAF is recruited at least in part via an interaction between PR and the BAF57 subunit of the complex. In a previous report we have described that acetylation of H3K14 in response to progesterone [30]. Now we show that H3K14ac, likely generated by PCAF, anchors the BAF complex, suggesting a mechanism for the cooperation between two types of chromatin remodeling activities. The recruited BAF catalyzes the ATP dependent displacement of histones H2A/H2B needed for NF1 to gain access to the promoter site. Thus synergism between the two transcription factors PR and NF1 is mediated by a cooperation between two chromatin remodeling machines, BAF and PCAF.

BAF interacts with PR and is necessary for induction of progesterone target genes in breast cancer cells

Activation of several hormone sensitive promoters exhibits SWI/SNF-dependence reflecting the requirement of chromatin remodeling [40,49–51]. There is evidence that glucocorticoid receptor recruits a Brg1-containing complex to promoters via protein-protein interaction with BAF250 [40], whereas androgen receptor (AR) and ERα can directly bind BAF57 [39,51]. We have described a progesterone dependent recruitment of Brg1 and Brm to the MMTV promoter in breast cancer cells and have shown that yeast SWI/SNF can displace H2A/H2B dimers from MMTV recombinant nucleosomes [6], but the nature of the complex recruited in intact cells and its function in gene activation was not known.

The human SWI/SNF complexes can have either Brm or Brg1 as ATPase subunits [52]. Although the two ATPases exhibit certain differences in their biological activities [53,54], they can partly compensate for each other in mouse cells [55]. We found that in T47D-MTVL cells depletion of Brm increases Brg1 levels and vice versa. This could be due to the existence of an excess of both free ATPases in equilibrium with the complex bound forms. If one of the ATPase is depleted the other will be incorporated to a higher extent in the SWI/SNF complex thus becoming more resistant to proteolytic degradation. A similar finding has been reported in mice lacking Brm [56].

The BAF complex is recruited to the MMTV promoter within minutes after progesterin treatment, likely through a direct interaction with the activated PR. The fact that PR was unable to form a complex with PBAF indicates that the receptor can discriminate between these two related machineries and promotes BAF recruitment to progesterin target promoters. Although BAF57 is present in BAF and PBAF complexes it is possible that hormone-dependent interaction with PR is only possible in the context of the BAF complex. Similar results have been previously reported for AR and ERα [38,39,51]. Depletion of BAF250 has a similar effect on MMTV induction as depletion of both Brg1 and Brm, confirming the importance of the BAF complex. BAF dependence is observed with other progesterone responsive genes, such as FOS and MYC, indicating that chromatin remodeling by BAF plays a more general role in progesterone gene regulation. However, as exemplified by the cyclin D1 gene, not all hormone responsive genes required BAF for induction, indicating the existence of alternative pathways for hormonal gene regulation. It is likely that other ATP-dependent remodeling complexes participate in regulation of MMTV and other progesterone regulated genes. In minichromosomes reconstituted in Drosophila embryo extracts NURF mediates synergy between recombinant PR and NF1 in a SWI/SNF independent manner [35]. The difference with our
Acetylation on histone H3K14 by PCAF is essential for hormonal induction by anchoring BAF to the promoter

The role of histone acetylation on MMTV activity has been controversial. We have observed that low concentration of HDAC inhibitors leading to moderate increase in acetylation, enhance MMTV transcription [37], whereas high concentrations completely abolish transcription [37,57]. In previous reports, we have demonstrated the co-recruitment of PCAF and SRC1 to the MMTV promoter following progesterin treatment [6,30]. The siRNA knockdown results presented here demonstrate that PCAF is one of the main HATs acting on the MMTV promoter, that its levels correlated with the extent of H3K14 acetylation, and that acetylation is necessary and important for progesterone activation of the MMTV promoter.

There have also been controversies over the nature of the histone modifications influencing binding of the SWI/SNF complex [58]. It was first claimed that acetylation of H4K8 recruits the SWI/SNF complex via Brg1, whereas acetylation of H3K9 and H3K14 is only important for the recruitment of TFIIID general transcription factors [43]. Two independent recent reports demonstrated that the bromodomain-containing ATPase Brg1 has the highest binding affinity to acetylated H3K14 peptide or doubly acetylated H3K9/K14 peptide, whereas binding to acetylated H4K8 peptide is insignificant [59,60]. Although H4 acetylation takes place very early after progesterone addition to T47D-MTVL cells (Figure 4B), we found here no binding of the BAF complex to acetylated H4 peptides (Figure 4A). In contrast, we show that components of the BAF complex bind to peptides containing acetylated H3K14, alone or in combination with other histone modifications. Furthermore, we quantify the interaction of components of BAF and PBAF to H3 acetylated peptides by SILAC. Our results indicate that compared to H3K9ac, H3K14ac is the major contributor to anchoring of these chromatin-remodeling complexes to nucleosomes. Several subunits of BAF and PBAF contain bromodomains that can bind acetylated residues. Obvious candidates are Brg1 and Bsm, but other subunits, such as BAF180, could cooperate on the recognition of H3K14ac by PBAF. Despite the fact that both BAF and PBAF can bind acetylated K14, only BAF is recruited to the MMTV promoter, indicating that H3K14ac participates in anchoring or retention of the recruited complex but is not sufficient for recruitment.

The colocalization of BAF and H3K14ac (Figure 3F) could reflect a general role of this histone mark to BAF anchoring in chromatin, but other explanations are possible. For instance, a common transcription factor could recruit BAF and HATs to the same chromatin regions. Alternatively, components of the BAF complex could be important for HATs recruitment. A combination of these hypotheses is also possible.

BAF mediates nucleosome remodeling leading to H2A/H2B displacement that facilitates NF1 binding

Following hormone treatment, PR is phosphorylated, forms a complex with activated Erk and Msk1 and this ternary complex binds the exposed HRE1 on the surface of the MMTV promoter nucleosome leading to modification of the H3 tail and displacement of a repressive complex [30]. PCAF is also recruited to the promoter and acetylation of H3K14 is observed 5 min after hormone treatment [30]. The activated ternary complex pPR-pErk-pMsk1 recruits BAF that initiates nucleosome remodeling, since inhibiting Erk or Msk1 activation blocks BAF recruitment and the subsequent steps. We have not addressed the initial kinetics of acetylation and BAF recruitment in sufficient detail and cannot propose a precise order of events. Moreover, we cannot exclude that PCAF interacts with BAF and that both complexes are recruited together.

In T47D-MTVL cells the BAF mediated chromatin remodeling event is a localized displacement of dimers of H2A/H2B from promoter nucleosome B, a catalytic activity exhibited by the purified yeast SWI/SNF complex on recombinant MMTV nucleosomes [6]. An earlier study with recombinant nucleosomes and SWI/SNF complexes from yeast suggest that both BAF and PBAF complexes would have the capacity to displace histones H2A/H2B as they share the relevant subunit, Swi3p [36]. This remodeling event is a prerequisite for enabling access of NF1 to its binding site in the MMTV promoter following hormone treatment, as demonstrated by the lack of H2A displacement and NF1 binding in BAF-depleted cells. We have previously shown that NF1 binding stabilizes the open conformation of the nucleosome allowing binding of further PR molecules to the internal HREs and subsequent activation of transcription [35]. A model representing our present view of the initial steps in progesterone activation of the MMTV promoter is shown in Figure 5. The model underlines the feed-forward cyclical nature of the activation process and explains why interfering with any of the initial steps has consequences for binding of all factors involved, PR, NF1, BAF and PCAF.

Briefly, after hormone induction activated PR binds first to the exposed HRE1 in a process that does not require chromatin remodeling, as this site is accessible [28]. Along with the activated PR, kinases, BAF and PCAF are recruited to the promoter chromatin. Histone H3 S10 phosphorylation and K14 acetylation promote displacement of an H1P1-containing repressive complex [30] and BAF anchoring, respectively. Now, BAF can displace histones H2A/H2B and thus facilitate NF1 binding. Bound NF1 stabilize the open conformation of the remodelled nucleosome exposes the previously hidden HREs allowing binding of further PR-BAF-kinases complexes and PCAF. Binding of PR to these previously hidden HREs is critical for the MMTV activation.

Finally, it is worth noting that we have not mentioned in these studies the possible role of linker histones. Our previous results [61] and those of other groups [62–64], suggest that changes histone H1 stoichiometry and phosphorylation by CyclinA/Cdk2 take place at different time points during the hormonal induction and are important for transcriptional activation. Future studies will be required to clarify the relationship of these changes to those reported in this study.

Materials and Methods

Cell culture and hormone treatments

T47D-MTVL breast cancer cells carrying one stably integrated copy of the luciferase reporter gene driven by the MMTV promoter [27] were routinely grown in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. For the experiments, cells were plated in RPMI medium without phenol red supplemented with 10% dextran-coated charcoal treated FBS (DCC/FBS) and 48 h later medium was replaced by fresh medium without serum.
Figure 5. Model for the initial steps of MMTV promoter activation. Before hormone addition the MMTV promoter is silent and associated with a repressive complex that includes HP1γ (step 1). After hormone addition the activated complex of pPR-pErk-pMsk, as well as PCAF and BAF, are recruited to the MMTV promoter. For simplicity PR is shown as a monomer, though the active form is a homodimer. Msk and PCAF phosphoacetylates H3 leading to H3S10phK14ac (step 2). This modification displaces the repressive complex and anchors the BAF complex, enabling ATP-dependent H2A/H2B displacement (step 3). The nucleosome opening facilitates NF1 binding generating a stable platform that exposes previously hidden HREs for the recruitment of additional PR and BAF complexes, coactivator and eventually promoter activation (step 4). Depletion of BAF prevents progression of the activation process to step 2: no histone displacement is observed, NF1 cannot bind and consequently less PR/BAF complexes are bound to the promoter. Depletion of PCAF has a similar effect, most likely by labilization of BAF binding, blocking the activation process at step 2.
doi:10.1371/journal.pgen.1000567.g005
After 24 h in serum-free conditions, cells were incubated with R5020 (10 nM) or vehicle (ethanol) for different times at 37°C.

**Transient transfections**

Cells were cultured into 6-well plates at a density of 4 x 10^5 cells/well and treated as indicated above. Transient transfections were performed using Lipofectamine 2000 (Invitrogen). cDNAs expressing PCAF and its deacetylase defective mutant (PCAF ΔHAT) were kindly provided by Tony Kouzarides (Cambridge, UK).

**Chromatin Immunoprecipitation (ChIP) and re-ChIP assays in cultured cells**

ChIP assays were performed as described [65] using the NF1 specific antibody (gift from Dr Naoko Tanese), the H2A antibody (gift from Stefan Dimitrov), anti-BAF180 (gift from Dr Weidong Wang), anti-PR (H190) and anti-Brg1 (H88), both from Santa Cruz, anti-SMARCA2/BRM (ab15597) from Abcam, anti-BAF57/SMARCE1 from Bethyl and anti-acyetyl(Lys14)-Histone H3 and anti-BAF250 from Upstate. Quantification of chromatin immunoprecipitation was performed by real time PCR using Roche Lightcycler (Roche). The fold enrichment of target sequence in the immunoprecipitated (IP) compared to input (Ref) fractions was calculated using the comparative Ct (the number of cycles required to reach a threshold concentration) method with the equation 2^(-ΔΔCt) as described [66]. Each of these values were corrected by the human β-globin gene and referred as relative abundance over time zero. Primers sequences are available on request. For re-ChIP assays, immunoprecipitations were sequentially washed as previously described [66]. Complexes were eluted with 10 mM DTT at 37°C for 30 min, diluted 50 times with dilution buffer, and immunoprecipitated with the indicated antibodies. The antibodies used for ChIPs assays are listed in Figure S5.

**RNA interference experiments**

All siRNAs were transfected into the T47D-MTVL cells using Lipofectamine 2000 (Invitrogen). After 48 h the medium was replaced by fresh medium without serum. After one day in serum-free conditions, cells were incubated with R5020 (10 nM) or vehicle (ethanol) for different times at 37°C. The down-regulation of Brg1, Brm, NF1, BAF57, BAF250, PCAF and SRC1 expression was determined by Western blotting. The siRNAs used are listed in Figure S5.

**RNA extraction and RT–PCR**

Total RNA was prepared and cDNA generated as previously described [30]. Quantification of LUC and GAPDH gene products was performed by real time PCR. Each value calculated using the standard curve method was corrected by the human GAPDH and expressed as relative RNA abundance over time zero. Primer sequences are available on request.

**Coimmunoprecipitation assay**

Cells were lysed and cell extracts (2 mg) were incubated with protein G/A agarose beads previously coupled with 6 μg of the corresponding antibodies or an unspecific control antibody. The immunoprecipitated proteins (IP) were eluted by boiling in SDS sample buffer. Inputs and IPs were analyzed by western blot using BRG1, BRM, BAF155, BAF170 and H3K14ac specific antibodies.

**Peptide pull down assays**

Nuclear extracts from T47D-MTVL breast cancer cells were prepared as described [67]. Peptide pull down assays were performed as described previously [68], with the exception of using 100 μg of nuclear extract during incubation of peptidedound beads. Synthetic biotinylated H3 and H4 peptides were either purchased from Upstate or were kind gifts from M. Vermeulen. For Western immunoblotting, antibodies against BRG1, BAF170, BAF155, PR (Santa Cruz), BRM (Abcam), BAF57, SNF5 (Bethyl) and H1 (Upstate 05-457) were used.

**Mass spectrometry of proteins**

After trypsin digestion of gel slices peptides were extracted, desalted using stage tips [69] and analyzed using a nano-HPLC. Agilent 1100 nanoflow system connected online to an LTQ-Orbitrap mass spectrometer (Thermo Fisher, Bremen). The mass spectrometer was operated in the data-dependent mode to automatically switch between MS and MS². The instrument was operated with ‘lock mass option’ as recently described [70]. Survey spectra were acquired with 60,000 resolution in the orbitrap, while acquiring up to five tandem mass spectra in the LTQ part of the instrument. The raw data files were analyzed with an in-house developed quantitative proteomics software MaxQuant, version 1.0.12.5 [71], in combination with the Mascot search engine (Matrix Science). The data was searched against a decoy human IPI database 3.37 including common contaminants. False discovery rates, both at the peptide and protein level were set to 1%. Minimal peptide length was set to 6 amino acids. False positive rates for peptides are calculated as described in [72].

**Supporting Information**

**Figure S1** Differential expression of BAF proteins in T47D-MTVL breast cancer cells. Nuclear extracts from T47D-MTVL cells were analyzed by western blotting with antibodies specific for the individual BAF proteins. Found at: doi:10.1371/journal.pgen.1000567.s001 (0.39 MB TIF)

**Figure S2** Knock down of BAF180 does not affect MMTV transcriptional activity. (A) BAF180 is recruited to the RARβ2 promoter. U937 cells (human promyelocytic leukemia cell line) were untreated (−) or treated (+) for 4 h with retinoic acid (RA) and subjected to ChIP assays with BAF200 and BAF180 specific antibodies. The precipitated DNA fragments were subjected to PCR analysis to test for the presence of sequences from −665 to −300 corresponding to the RARβ2 promoter. Lower Panel: expression of BAF180 and BAF200 proteins in U937 cells. (B) Knock down of BAF180 does not affect MMTV transcriptional activity. Left: T47D-MTVL cells were transfected either with control siRNA or with siRNA against BAF180. After 48 h the medium was replaced by fresh medium without serum. After one day in serum-free conditions, cells were lysed and the levels of BAF 180 and tubulin were determined by Western blotting. Right: T47D-MTVL cells were transfected with Control or BAF 180 siRNAs in RPMI medium and cultured for 48 h. After one day in serum-free conditions, cells were incubated with 10 nM R5020 for 2 h and total RNA was prepared, cDNA was generated and used as template for real time PCR with specific Luciferase and GAPDH primers. Each luciferase mRNA value was corrected by the GAPDH mRNA level and is expressed as relative RNA abundance over time zero. The values represent the mean and standard deviation from 3 experiments performed in duplicate. Found at: doi:10.1371/journal.pgen.1000567.s002 (0.17 MB TIF)

**Figure S3** Schematic representation of the SILAC-based histone pull down approach. (A) SILAC peptide pull-down using unmodified H3 (grey ovals), H3K9ac (B, blue ovals), and H3K14ac (C, red ovals) peptide. The spectra show the relative...
binding of Brm (1), BAF200 (2), Polybromo/BAF180 (3), and Brg1 (4) to unmodified and modified peptides.

Figure S4  Brm and Brg are required for the interaction of BAF and PBAF complexes with the H3K14ac mark. (A) Nuclear extracts derived from T47D-MTVM cells transfected with control and Brm and Brg siRNAs were used for pulldown experiments with the indicated H3 tail peptides coupled to beads. Immunoblotting was performed for the presence of BAF57 and H1. (B) Nuclear extracts derived from T47D-MTVM cells transfected with control and Brm and Brg siRNAs were used for immunoprecipitation either with BAF57 antibody or with normal rabbit IgG as a negative control (IgG). The immunoprecipitates (IP) were analyzed by western blotting with BAF155 and BAF170 specific antibodies.

Found at: doi:10.1371/journal.pgen.1000567.s004 (0.22 MB TIF)

Figure S5  siRNAs and antibodies used for ChIP assays in the present study.

Found at: doi:10.1371/journal.pgen.1000567.s005 (0.67 MB TIF)

Acknowledgments

We thank to Naoko Tanese, NYU, New York, USA, for anti NFI antibody; Stefan Dimitrov, CNR Grenoble, for histone H2A antibodies; and Borja Belandia, IIB, Madrid, Spain, for BAF57 constructs.

Author Contributions

Conceived and designed the experiments: GPV MB. Performed the experiments: GPV RZ ASN AL JFM FLD MV. Analyzed the data: GPV RZ AS AL MM. Contributed reagents/materials/analysis tools: MV MM. Wrote the paper: GPV MB.

References

1. Lager K, Mader AW, Richmond RK, Sargent DF, Richmond TJ (1997) Crystal structure of the nucleosome core particle at 2.6 A resolution. Nature 389: 251–260.
2. Aalton JD, Kingston RE (2000) What does ‘chromatin remodeling’ mean? Trends Biochem Sci 25: 548–555.
3. Whitlehouse I, Rando OJ, Deltow J, Tsukiyama T (2007) Chromatin remodelling at promoters suppresses antisense transcription. Nature 450: 1031–1035.
4. Mohrman L, Verrijzer CP (2005) Composition and functional specificity of SWI2/SNF2 class chromatin remodeling complexes. Biochem Biophys Acta 1731: 59–73.
5. Bruno M, Haus A, Stockdale C, Rencurel C, Ferreira H, et al. (2003) Histone H2A/H2B dimer exchange by ATP-dependent chromatin remodeling activities. Mol Cell 12: 1599–1606.
6. Vicent GP, Nath AS, Smith CL, Peterson CL, Dimitrov S, et al. (2004) DNA instruction of displacement of histones H2A and H2B at an inducible promoter. Mol Cell 16: 439–452.
7. Cairns BR, Schlichter A, Erdjument-Bromage H, Tempst P, Kornberg RD, et al. (1999) Two functionally distinct forms of the RSC nucleosome-remodeling complex, containing essential AT hook, BAH, and bromodomains. Mol Cell 5: 713–723.
8. Wang W (2003) The SWI/SNF family of ATP-dependent chromatin remodelers: similar mechanisms for diverse functions. Curr Top Microbiol Immunol 274: 143–169.
9. Xue Y, Camann JC, Lee CS, Nie Z, Yang D, et al. (2000) The human SWI- SNF2 chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes. Proc Natl Acad Sci U S A 97: 19015–19020.
10. Yan Z, Cui K, Murray DM, Ling C, Xue Y, et al. (2003) PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. Genes Dev 19: 1662–1667.
11. Chiavino P, Allis CD (2004) Signaling to chromatin through histone modifications. Mol Cell 10: 475–487.
12. Carrozza MJ, Utley RT, Workman JL, Cote J (2003) The diverse functions of histone acetyltransferase complexes. Trends Genet 19: 321–329.
13. Whitehouse I, Rando OJ, Delrow J, Tsukiyama T (2007) Chromatin
14. structure of the nucleosome core particle at 2.8 Å resolution. Nature 389:
15. 723–737.
16. Bhattacharjee RN, Archer TK (2006) Transcriptional silencing of the mouse mammary tumor virus promoter through chromatin remodeling is concomitant with histone H1 phosphorylation and histone H3 hyperphosphorylation at M phase. Virology 346: 1–6.
17. Muchardt C, Yanis M (1993) A human homologue of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor. Embo J 12: 4279–4290.
18. Venditti P, Di Croce L, Kauer M, Blank T, Becker PB, et al. (1998) Assembly of MMTV promoter minichromosomes with positioned nucleosomes precludes NFI access but not restriction enzyme cleavage. Nucleic Acids Res 26: 3657–3666.
19. Di Croce L, Koop R, Venditti P, Westphal HM, Nightingale KP, et al. (1999) Two-step synergism between the progesterone receptor and the DNA-binding domain of nuclear factor 1 on MMTV minichromosomes. Mol Cell 4: 45–54.
20. Yang X, Zaurin R, Beato M, Peterson CL (2007) SWI/Snf controls SWI/SNF assembly and ATP-dependent H2A/H2B displacement. Nat Struct Mol Biol 14: 540–547.
21. Bartsch J, Truss M, Bode J, Beato M (1996) Moderate increase in histone acetylation activates the mouse mammary tumor virus promoter and remodels its nucleosome structure. Proc Natl Acad Sci U S A 93: 10741–10746.
22. Garcia-Peiderero JM, Kiskinis E, Parker MG, Belandia B (2006) The SWI/SNF chromatin remodeling subunit BAF57 is a critical regulator of estrogen receptor function in breast cancer cells. J Biol Chem 281: 22656–22664.
23. Liu E, Andrews P, Burd CJ, Williams E, Marshall T, Rossouw G, et al. (2005) BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Mol Cell Biol 25: 2200–2215.
24. Nez X, Xue Y, Yang D, Zhou S, Deros J, et al. (2000) A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol 20: 8079–8088.
25. Sif S (2004) ATP-dependent nucleosome remodeling complexes: enzymes tailored to deal with chromatin. J Cell Biol 91: 1087–1088.
42. Hassan AH, Procasson P, Nede KE, Galasinski SC, Chandy M, et al. (2002) Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes. Cell 111: 369–379.

43. Argoliti T, Chen G, Thanos D (2002) Deciphering the transcriptional histone acetylation code for a human gene. Cell 111: 381–392.

44. Koskoniemi A, Talainis I (2008) Histone modifications defining active genes persist after transcriptional and mitotic inactivation. Embo J 24: 347–357.

45. Schulze WX, Mann M (2004) A novel proteomic screen for peptide-protein interactions. J Biol Chem 279: 10765–10764.

46. Gronostajski RM (2000) Roles of the NFI/CTF gene family in transcription and development. Gene 249: 31–45.

47. Kane R, Finlay D, Lamb T, Martin F (2000) Transcription factor NF1 expression in involving mammalian gland. Adv Exp Med Biol 480: 117–122.

48. Hebbel PB, Archer TK (2007) Chromatin-dependent cooperativity between site-specific transcription factors in vivo. J Biol Chem 282: 8284–8291.

49. Marshall TW, Link KA, Petre-Dervan CE, Knowles KE (2003) Differential requirement of SWI/SNF for androgen receptor activity. J Biol Chem 278: 30605–30613.

50. Fryer CJ, Archer TK (1998) Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature 393: 68–91.

51. Bandalho B, Orford RJ, Hurst HC, Parker MG (2002) Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. Embo J 21: 4094–4103.

52. Wang W, Xue Y, Zhou S, Kuo A, Cairns BR, et al. (1996) Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev 10: 2117–2130.

53. Mizutani T, Ito T, Nishina M, Yamamichi N, Watanabe A, et al. (2002) Maintenance of integrated progerial gene expression requires Bm, a catalytic subunit of SWI/SNF complex. J Biol Chem 277: 15059–15064.

54. Wang F, Zhang R, Beischlag TV, Muchardt C, Yaniv M, et al. (2004) Roles of Brahma and Brahma/SWI2-related gene 1 in hypoxic induction of the erythropoietin gene. J Biol Chem 279: 46733–46741.

55. Reyes JC, Barra J, Muchardt C, Camus A, Babinet C, et al. (1998) Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alph). Embo J 17: 6979–6991.

56. Peterson CL, Hershkoewitz I (1992) Characterization of the yeast SWI1, SWI2, and SWI3 genes, which encode a global activator of transcription. Cell 68: 573–583.

57. Mulholland NM, Soeth E, Smith CL (2003) Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodelling and increased histone acetylation. Oncogene 22: 4807–4818.

58. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403: 41–45.

59. Shen W, Xu C, Huang W, Zhang J, Carlson JE, et al. (2007) Solution structure of human Brg1 bromodomain and its specific binding to acetylated histone tails. Biochemistry 46: 2100–2110.

60. Singh M, Poppovic GM, Krajewski M, Holak TA (2007) Structural ramification for acetyl-histone recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex. Chembiochem 8: 1308–1316.

61. Koop R, Di Croce L, Beato M (2003) Histone H1 enhances synergistic activation of the MMTV promoter in chromatin. Embo J 22: 588–599.

62. Bhattacharjee RN, Banks GC, Trotter KW, Lee HL, Archer TK (2001) Histone H1 phosphorylation by Cdk2 selectively modulates mouse mammary tumor virus transcription through chromatin remodeling. Mol Cell Biol 21: 5417–5425.

63. Narayanam R, Adugan AA, Edwards DP, Weigel NL (2005) Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol 25: 264–277.

64. Bresnick EH, Bustin M, Marraud V, Richard-Foy H, Hager GL (1992) The transcriptionally-active MMTV promoter is depleted of histone H1. Nucleic Acids Res 20: 273–278.

65. Strutt H, Paro R (1999) Mapping DNA target sites of chromatin proteins in vivo by formaldehyde crosslinking. Methods Mol Biol 119: 455–467.

66. Shang Y, Myers M, Brown M (2002) Formation of the androgen receptor transcription complex. Mol Cell 9: 601–610.

67. Dignam JD, Lebovitz RM, Roeder RG (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475–1489.

68. Vermeulen M, Mulder KW, Denissen S, Pijnappel WW, van Schaik FM, et al. (2007) Selective anchoring of TFIIID to nucleosomes by trimethylhication of histone H3 lysine 4. Cell 131: 58–69.

69. Rappalher J, Ishihama Y, Mann M (2003) Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem 75: 663–670.

70. Olsen JV, de Godoy LM, Li G, Macek B, Mortensen P, et al. (2005) Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics 4: 2010–2021.

71. Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantitation. Nat Biotechnol 26: 1367–1372.

72. Nesvizhskii AI, Vitek O, Aebersold R (2007) Analysis and validation of proteomic data generated by tandem mass spectrometry. Nat Methods 4: 787–797.